Wells Fargo analyst Cerena Chen lowered the firm’s price target on Amphastar (AMPH) to $35 from $40 and keeps an Overweight rating on the shares. The firm says that continued expectations for 2 launches this year despite recent CRLs is reassuring though it notes sales contribution would be more meaningful in 2026. Good Baqsimi and Primatene growth make Wells less concerned about competitive pressure elsewhere.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Cautious Hold Rating for Amphastar Pharmaceuticals Amid Competitive Pressures and Revenue Challenges
- Amphastar Pharmaceuticals: Neutral Stance Amid Mixed Financial Outlook and Pipeline Uncertainty
- Amphastar Pharmaceuticals Reports Q1 2025 Earnings
- Amphastar Pharmaceuticals Inc (AMPH) Q1 Earnings Cheat Sheet
- Amphastar price target lowered to $31 from $36 at BofA